Enhanced bridging function and augmented monocyte adhesion by lipoprotein lipase N9: Insights into increased risk of coronary artery disease in N9 carriers

Atherosclerosis

Volumn 166, Issue 2, 2003, Pages 243-251

  Fisher, Rachel M ^a,d   Benhizia, Ferdaous ^a   Schreiber, Renate ^a   Makoveichuk, Elena ^b   Putt, Wendy ^a   Al Haideri, Maysoon ^c   Deckelbaum, Richard J ^c   Olivecrona, Gunilla ^b   Humphries, Steve E ^a   Talmud, Philippa J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UMEÅ UNIVERSITY   (Sweden)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bridging function; Chinese hamster ovary cells; Heparan sulphate proteoglycans; Lipoprotein lipase; Low density lipoprotein; Monocytes; Oxidised low density lipoprotein

Indexed keywords

COMPLEMENTARY DNA; DIMER; HEPARIN; HEPARIN LYASE; LIPOPROTEIN LIPASE; MONOMER; PROTEOGLYCAN;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR RISK; CELL ADHESION; CELL SURFACE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME PURIFICATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

BASE SEQUENCE; CELL ADHESION; CELLS, CULTURED; CORONARY ARTERIOSCLEROSIS; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LIPOPROTEIN LIPASE; MOLECULAR SEQUENCE DATA; MONOCYTES; PROBABILITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 12244292721     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00337-4     Document Type: Article

References (37)

1. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 3:1996;213-219.
2. Olivecrona G., Olivecrona T. Triglyceride lipases and atherosclerosis. Curr. Opin. Lipidol. 6:1995;291-305.
3. Beisiegel U., Weber W., Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA. 88:1991;8342-8346.
4. Williams K.J., Fless G.M., Petrie K.A., Snyder M.L., Brocia R.W., Swenson T.L. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J. Biol. Chem. 267:1992;13284-13292.
5. Merkel M., Kako Y., Radner H., et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;13841-13846.
6. Eckel R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. New Engl. J. Med. 320:1989;1060-1068.
7. Ylä-Harttuala S., Lipton B.A., Rosenfeld M.E., Goldberg I.J., Steinberg D., Witztum J.L. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 88:1991;10143-10147.
8. Clee S.M., Bissada N., Miao F., et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J. Lipid Res. 41:2000;521-531.
9. Renier G., Desfaits A.C., Lambert A., Mikhail R. Role of oxidant injury on macrophage lipoprotein lipase (LPL) production and sensitivity to LPL. J. Lipid Res. 37:1996;799-809.
10. Hendriks W.L., van der Boom H., van Vark L.C., Havekes L.M. Lipoprotein lipase stimulates the binding and uptake of moderately oxidized low-density lipoprotein by J774 macrophages. Biochem. J. 314:1996;563-568.
11. Obunike J.C., Paka S., Pillarisetti S., Goldberg I.J. Lipoprotein lipase can function as a monocyte adhesion protein. Arterioscler. Thromb. Vasc. Biol. 17:1997;1414-1420.
12. Mamputu J.-C., Renier G. Differentiation of human monocytes to monocyte-derived macrophages is associated with increased lipoprotein lipase-induced tumor necrosis factor-a expression and production. A process involving cell surface proteoglycans and protein kinase C. Arterioscler. Thromb. Vasc. Biol. 19:1999;1405-1411.
13. Babaev V.R., Fazio S., Gleaves L.A., Carter K.J., Semenkovich C.F., Linton M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest. 103:1999;1697-1705.
14. Fisher R.M., Humphries S.E., Talmud P.J. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis. 135:1997;145-159.
15. Hokanson J.E. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int. J. Clin. Lab. Res. 27:1997;24-34.
16. Wittrup H.H., Tybjærg-Hansen A., Steffensen R., Deeb S.S., Brunzell J.D., Jensen G., Nordestgaard B.G. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen City Heart Study. Arterioscler. Thromb. Vasc. Biol. 19:1999;1535-1540.
17. Mailly F., Tugrul Y., Reymer P.W.A., et al. A common variant in the gene for lipoprotein lipase (Asp9→Asn): functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 15:1995;468-478.
18. Gerdes C., Fisher R.M., Nicaud V., Boer J., Humphries S.E., Talmud P.J., Faergeman O. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations. Studies in the fasting and postprandial states: the European Atherosclerosis Research studies. Circulation. 96:1997;733-740.
19. Wittrup H.H., Tybjærg-Hansen A., Abildgaard S., Steffensen R., Schnohr P., Nordestgaard B.G. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischaemic heart disease. J. Clin. Invest. 99:1997;1606-1613.
20. Zhang H., Henderson H., Gagne S.E., Clee S.M., Miao L., Liu G., Hayden M.R. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochim. Biophys. Acta. 1302:1996;159-166.
21. Wittrup H.H., Tybjærg-Hansen A., Nordestgaard B.G. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 99:1999;2901-2907.
22. Kastelein J.J., Groenemeyer B.E., Hallman D.M., et al. The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. Clin. Genet. 53:1998;27-33.
23. 9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation. 94:1996;1913-1918.
24. Talmud P.J., Bujac S.R., Hall S., Miller G.J., Humphries S.E. Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers. Atherosclerosis. 149:2000;75-81.
25. Bebbington C.R. Expression of antibody genes in nonlymphoid mammalian cells. Methods. 2:1991;136-145.
26. O'Keeffe B., Fong Y., Chen D., Zhou S., Zhou Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated Tat stimulation of HIV-1 transcription. J. Biol. Chem. 275:2000;279-287.
27. Potenz R., Lo J.-Y., Zsigmond E., Smith L.C., Chan L. Human lipoprotein lipase: production in vitro, purification, and generation of polyclonal antibody. Methods Enzymol. 263:1996;319-326.
28. Celi F.S., Zenilman M.E., Shuldiner A.R. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res. 21:1993;1047.
29. Bergö M., Olivecrona G., Olivecrona T. Forms of lipoprotein lipase in rat tissues: in adipose tissue the proportion of inactive lipase increases on fasting. Biochem. J. 313:1996;893-898.
30. Greilberger J., Schmut O., Jürgens G. In vitro interactions of oxidatively modified LDL with type I, II, III, IV, and V collagen, laminin, fibronectin, and poly-D-lysine. Arterioscler. Thromb. Vasc. Biol. 17:1997;2721-2728.
31. Markwell M.A., Haas S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:1978;206-210.
32. Makoveichuk E., Lookene A., Olivecrona G. Mild oxidation of lipoproteins increases their affinity for surfaces covered by heparan sulfate and lipoprotein lipase. Biochem. Biophys. Res. Commun. 252:1998;703-710.
33. Borén J., Lookene A., Makoveichuk E., et al. Binding of low density lipoproteins to lipoprotein lipase is dependent on lipids but not on apolipoprotein B. J. Biol. Chem. 276:2001;26916-26922.
34. Berryman D.E., Bensadoun A. Heparan sulfate proteoglycans are primarily responsible for the maintenance of enzyme activity, binding, and degradation of lipoprotein lipase in Chinese hamster ovary cells. J. Biol. Chem. 270:1995;24525-24531.
35. Lookene A., Skottova N., Olivecrona G. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur. J. Biochem. 222:1994;395-403.
36. Fickl H., van Antwerpen V.L., Richards G.A., van der Westhuyzen D.R., van der Walt R., van der Merwe C.A., Anderson R. Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers. Atherosclerosis. 124:1996;75-81.
37. Bergmann S., Siekmeier R., Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir. Physiol. 114:1998;269-275.